UK pharma major GlaxoSmithKline (LSE: GSK) has named Jack Bailey as president of its US pharma unit.
He replaces Deirdre Connelly, who held the role for six years. Mr Bailey most recently served as senior vice president for policy, payers and vaccines at the company.
GSK registered a 12% drop in US pharmaceuticals sales last year, as the company’s best-selling product, asthma drug Advair (fluticasone propionate), felt the effects of patent expiry and the loss of market share.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze